These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31925942)

  • 1. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
    Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
    Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
    Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis viewing for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: application of nomogram and decision curve analysis.
    Fei Z; Qiu X; Li M; Chen C; Li Y; Huang Y
    Jpn J Clin Oncol; 2020 Feb; 50(2):159-168. PubMed ID: 31711182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
    Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
    Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma.
    Liu Y; Zhang J; Wang J; Wu R; Huang X; Wang K; Qu Y; Chen X; Li Y; Zhang Y; Yi J
    Radiol Oncol; 2022 Dec; 56(4):479-487. PubMed ID: 36503717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: A study based on Epstein-Barr virus DNA biological responses.
    Yang K; Li M; Zhu J; Zeng L; Tian J; Xie W; Shou A; Li Y; Li G
    Head Neck; 2021 Jun; 43(6):1838-1847. PubMed ID: 33605501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
    Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy.
    Zhang C; Wang SF; Zhang YL; Teng CX
    BMC Cancer; 2024 Aug; 24(1):1012. PubMed ID: 39148032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of platelet‑to‑albumin ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a retrospective study of 858 cases.
    Hua X; Xu F; Shi W; Long ZQ; Huang X; Duan FF; Wang SF; Zhang C; Wang MD; Ni WQ; Xia W; Chen JY; Gao YS
    BMC Cancer; 2024 Jun; 24(1):762. PubMed ID: 38918690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
    Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.
    Pan Y; Chen Z; Hong W; Huang Z; Li Y; Cai S; Lai J; Lu J; Qiu S
    BMC Cancer; 2024 May; 24(1):578. PubMed ID: 38734620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.